Financial Supervisory Service requests correction of ToolGen's 700 billion won rights offering registration statement due to false statements and omissions, effectiveness suspended
The Financial Supervisory Service judged that the securities registration statement filed by ToolGen on June 22 for a 700 billion won rights offering contained issues such as improper form, false statements or omissions of material facts, and unclear descriptions that could hinder investor decision-making, and requested a corrected filing on July 2.
Consequently, the registration statement is considered not accepted and its effectiveness has been suspended. The subscription date and other issuance schedules may change, and if a corrected filing is not submitted within three months, the registration will be withdrawn.
ToolGen planned to raise 700 billion won through the issuance of 777,000 new shares representing 8.64% dilution, with funds allocated to patent litigation costs of 263 billion won, R&D expenses of 290 billion won, and SG&A of 148 billion won.
The company had only 5.7 billion won in cash and cash equivalents as of end-Q1 2026, accumulated deficit of 170.5 billion won, and persistent operating losses. Largest shareholder Genexine planned to subscribe only about 10% of its allotted shares.
[AI Summary]The regulatory correction request poses a significant risk to the rights offering timeline. If the funding is delayed or canceled due to the suspension, ToolGen's liquidity crisis could intensify. Investors should closely monitor whether a corrected filing is submitted and its contents.
KOSDAQ Filing Information
Request for Submission of Correction Report (Securities Registration Statement (Equity Securities) Submitted on June 22, 2026)